Akorn Receives a Hold from RBC Capital

By Austin Angelo

In a report released yesterday, Randall Stanicky from RBC Capital reiterated a Hold rating on Akorn (NASDAQ: AKRX), with a price target of $34. The company’s shares opened today at $33.63, close to its 52-week high of $35.40.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -8.2% and a 37.9% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Akorn is Hold and the average price target is $34, representing a 1.1% upside.

In a report issued on July 17, Jefferies also reiterated a Hold rating on the stock with a $34 price target.

The company has a one year high of $35.40 and a one year low of $17.61. Currently, Akorn has an average volume of 2.28M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akorn, Inc. is a niche pharmaceutical company that develops, manufactures and markets generic and prescription pharmaceuticals, as well as, animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health segments.